title: Management and outcome of patients with established coronary artery disease: the Euro Heart Survey on coronary revascularization.
abstract: OBJECTIVE
  The purpose of the Euro Heart Survey Programme of the European Society of Cardiology is to evaluate to which extent clinical practice endorses existing guidelines as well as to identify differences in population profiles, patient management, and outcome across Europe. The current survey focuses on the invasive diagnosis and treatment of patients with established coronary artery disease (CAD).
  
  
  RESULTS
  Between November 2001 and March 2002, 7769 consecutive patients undergoing invasive evaluation at 130 hospitals (31 countries) were screened for the presence of one or more coronary stenosis >50% in diameter. Patient demographics and comorbidity, clinical presentation, invasive parameters, treatment options, and procedural techniques were prospectively entered in an electronic database (550 variables+29 per diseased coronary segment). Major adverse cardiac events (MACE) were evaluated at 30 days and 1 year. Out of 5619 patients with angiographically proven coronary stenosis (72% of screened population), 53% presented with stable angina while ST elevation myocardial infarction (STEMI) was the indication for coronary angiography in 16% and non-ST segment elevation myocardial infarction or unstable angina in 30%. Only medical therapy was continued in 21%, whereas mechanical revascularization was performed in the remainder [percutaneous coronary intervention (PCI) in 58% and coronary artery bypass grafting (CABG) in 21%]. Patients referred for PCI were younger, were more active, had a lower risk profile, and had less comorbid conditions. CABG was performed mostly in patients with left main lesions (21%), two- (25%), or three-vessel disease (67%) with 4.1 diseased segments, on average. Single-vessel PCI was performed in 82% of patients with either single- (45%), two- (33%), or three-vessel disease (21%). Stents were used in 75% of attempted lesions, with a large variation between sites. Direct PCI for STEMI was performed in 410 cases, representing 7% of the entire workload in the participating catheterization laboratories. Time delay was within 90 min in 76% of direct PCI cases. In keeping with the recommendations of practice guidelines, the survey identified under-use of adjunctive medication (GP IIb/IIIa receptor blockers, statins, and angiotensin-converting enzyme-inhibitors). Mortality rates at 30 days and 1 year were low in all subgroups. MACE primarily consisted of repeat PCI (12%).
  
  
  CONCLUSIONS
  The current Euro Heart Survey on coronary revascularization was performed in the era of bare metal stenting and provides a global European picture of the invasive approach to patients with CAD. These data will serve as a benchmark for the future evaluation of the impact of drug-eluting stents on the practice of interventional cardiology and bypass surgery.
authors.affiliation: Department of Cardiology, Erasmus MC, Thoraxcenter, Rotterdam, The Netherlands.
authors.forename: M J
authors.initials: MJ
authors.lastname: Lenzen
authors.forename: E
authors.initials: E
authors.lastname: Boersma
authors.forename: M E
authors.initials: ME
authors.lastname: Bertrand
authors.forename: W
authors.initials: W
authors.lastname: Maier
authors.forename: C
authors.initials: C
authors.lastname: Moris
authors.forename: F
authors.initials: F
authors.lastname: Piscione
authors.forename: U
authors.initials: U
authors.lastname: Sechtem
authors.forename: E
authors.initials: E
authors.lastname: Stahle
authors.forename: P
authors.initials: P
authors.lastname: Widimsky
authors.forename: P
authors.initials: P
authors.lastname: de Jaegere
authors.forename: W J M
authors.initials: WJ
authors.lastname: Scholte op Reimer
authors.forename: N
authors.initials: N
authors.lastname: Mercado
authors.forename: W
authors.initials: W
authors.lastname: Wijns
mesh_terms: D000789:Angina, Unstable / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D001026:Coronary Artery Bypass / Q000379:methods; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000628:therapy*; D023921:Coronary Stenosis / Q000175:diagnosis / Q000628:therapy*; D004812:Epidemiologic Methods; D005060:Europe; D005260:Female; D019983:Guideline Adherence; D006306:Health Surveys; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000628:therapy; D009204:Myocardial Revascularization / Q000379:methods*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D017410:Practice Guidelines as Topic; D011364:Professional Practice / Q000592:standards; D015607:Stents; D016896:Treatment Outcome
chemical_list: D019039:Platelet Glycoprotein GPIIb-IIIa Complex